Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Long-Term Deferred Tax for 3 consecutive years, with $59.4 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 79.82% year-over-year to $59.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $59.4 million (up 79.82% YoY) and the FY2025 annual result came in at $59.4 million, up 105.23% from the prior year.
• Long-Term Deferred Tax rose to $59.4 million in Q4 2025 per TLX's latest filing, from $33.0 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for TLX reached as high as $59.4 million in Q4 2025 and fell as low as $14.4 million in Q4 2023.
• A 3-year average of $35.6 million and a median of $33.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 128.52% — and 2025, when it surged 79.82%.
• Year by year, Long-Term Deferred Tax stood at $14.4 million in 2023, then soared by 128.52% to $33.0 million in 2024, then jumped by 79.82% to $59.4 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $59.4 million, $33.0 million, and $14.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.